Bibliography
- Tarver T. Cancer Facts & Figures 2012. American Cancer Society (ACS). J Consum Health Internet 2012;16(3):366-7
- Von Hoff D, Ramanathan R, Borad M, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a Phase I/II Trial. J Clin Oncol 2011;29(34):4548-54
- John P, Butler H, Saif MW. Congestive heart failure secondary to gemcitabine nab-paclitaxel in patients with pancreatic cancer. Anticancer Res 2014;34(12):7267-70
- Hoy SM. Albumin-bound paclitaxel: a review of its use for the first-line combination treatment of metastatic pancreatic cancer. Drugs 2014;74(15):1757-68
- Authier N, Gillet JP, Fialip J, et al. Assessment of neurotoxicity following repeated cremophor/ethanol injections in rats. Neurotox Res 2001;3(3):301-6
- Postma TJ, Vermorken JB, Liefting AJ, et al. Paclitaxel-induced neuropathy. Ann Oncol 2004;6(5):484-94
- Brat DJ, Windebank AJ, Brimijoin S. Emulsifier for intravenous cyclosporine inhibits neurite outgrowth, causes deficits in rapid axonal transport and leads to structural abnormalities in differentiating N1E.115 neuroblastoma. J Pharmacol Exp Ther 1992;261(2):803-10
- Viúdez A, Ramírez N, Hernández-García I, et al. Nab-paclitaxel: a flattering facelift. Crit Rev Oncol Hematol 2014;92(3):166-80
- Alvarez R, Musteanu M, Garcia-Garcia E, et al. Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. Br J Cancer 2013;109(4):926-33
- Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369(18):1691-703
- Senkus E, Jassem J. Cardiovascular effects of systemic cancer treatment. Cancer Treat Rev 2011;37(4):300-11
- Provenzano PP, Cuevas C, Chang AE, et al. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 2012;21(3):418-29
- Yano S, Zhang Y, Miwa S, et al. Spatial-temporal FUCCI imaging of each cell in a tumor demonstrates locational dependence of cell cycle dynamics and chemoresponsiveness. Cell Cycle 2014;13(13):2110-19
- Yano S, Zhang Y, Zhao M, et al. Tumor-targeting Salmonella typhimurium A1-R decoys quiescent cancer cells to cycle as visualized by FUCCI imaging and become sensitive to chemotherapy. Cell Cycle 2014;13(24):3683-8
- Yano S, Tazawa H, Hashimoto Y, et al. A genetically engineered oncolytic adenovirus decoys and lethally traps quiescent cancer stem-like cells into S/G2/M phases. Clin Cancer Res 2013;19(23):6495-505
- Hoffman RM, Jacobsen SJ. Reversible growth arrest in simian virus 40-transformed human fibroblasts. Proc Natl Acad Sci USA 1980;77(12):7306-10
- Yano S, Li S, Han Q, et al. Selective methioninase-induced trap of cancer cells in S/G2 phase visualized by FUCCI imaging confers chemosensitivity. Oncotarget 2014;5(18):8729-36
- Stern PH, Hoffman RM. Enhanced in vitro selective toxicity of chemotherapeutic agents for human cancer cells based on a metabolic defect. J Natl Cancer Inst 1986;76(4):629-34